NCT03391050View on ClinicalTrials.gov

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

August 8, 2018

Study Completion Date

August 8, 2018

Conditions

Melanoma

Interventions

DRUG

APR-246

Intravenous infusion

DRUG

Dabrafenib

Oral administration

Trial Locations (3)

1000

Institut Jules Bordet, Brussels

2650

Universitair Ziekenhuis Antwerpen, Edegem

5000

CHU UCL Namur - site Sainte-Elisabeth, Namur

Sponsors

Lead Sponsor

Aprea Therapeutics

Collaborators (1)

Jules Bordet Institute

All Listed Sponsors

collaborator

Jules Bordet Institute

OTHER

lead

Aprea Therapeutics

INDUSTRY